期刊文献+

cT1-2N1M0期乳腺癌新辅助化疗和改良根治术后腋窝淋巴结转移0~3枚患者术后放疗的生存分析 被引量:9

Survival analysis of postmastectomy radiotherapy for breast cancer staged in cT1-2N1M0 after neoadjuvant chemotherapy with 0-3 metastatic lymph nodes
原文传递
导出
摘要 目的探讨cT1-2N1M0期乳腺癌新辅助化疗和改良根治术后达到腋窝淋巴结转移0~3枚的患者行术后放疗的价值。方法回顾性分析2000年1月1日至2014年12月31日本院收治的128例临床诊断为T1-2N1M0期乳腺癌患者的临床资料,所有患者均完成新辅助化疗和改良根治手术,术后腋窝淋巴结转移数为0~3枚。根据有无术后放疗将患者分为放疗组(n=87)和未放疗组(n=41),两组术后腋窝淋巴结转移达1~3枚(ypN1)患者分别为43、11例,术后腋窝淋巴结转移0枚(ypN0)患者分别为44、30例。采用Kaplan-Meier法计算患者5年无局部/区域复发生存(LRFS)率、无瘤生存(DFS)率和总生存(OS)率,并进行log-rank检验,单因素分析患者临床特征和治疗对预后的影响。结果128例患者的5年LRFS率、DFS率和OS率分别为91.4%、82.8%和93.0%。放疗组和未放疗组患者的5年LRFS率分别为94.3%和85.4%,差异无统计学意义(χ^2=3.055,P=0.080);5年DFS率分别为89.7%和68.3%,差异有统计学意义(χ^2=9.312,P=0.005);5年OS率分别为94.3%和90.2%,差异无统计学意义(χ^2=0.810,P=0.368)。亚组分析中,放疗组和未放疗组术后达ypN1患者的5年LRFS率分别为93.0%和72.7%,差异有统计学意义(χ^2=4.248,P=0.039);5年DFS率分别为88.4%和63.6%,差异有统计学意义(χ^2=4.525,P=0.033);5年OS率分别为90.7%和81.8%,差异无统计学意义(χ^2=0.713,P=0.399)。放疗组和未放疗组患者术后ypN0患者的5年LRFS率分别为95.5%和90.0%,差异无统计学意义(χ^2=0.872,P=0.350);5年DFS率分别为90.9%和70.0%,差异有统计学意义(χ^2=5.439,P=0.019);5年OS率分别为97.7%和93.3%,差异无统计学意义(χ^2=0.876,P=0.349)。单因素分析结果显示,年龄(χ^2=11.709,P=0.001)和有无脉管瘤栓(χ^2=7.608,P=0.006)是5年LRFS的影响因素,有无术后放疗(χ^2=9.312,P=0.002)是5年DFS的影响因素,年龄(χ^2=6.093,P=0.014)和激素受体状态(χ^2=3.974,P=0.046)是OS的影响因素。结论cT1-2N1M0期乳腺癌经新辅助化疗和改良根治术后ypN1的患者,行术后放疗有局部控制获益,并能改善患者DFS;而cT1-2N1M0期乳腺癌经新辅助化疗和改良根治术后ypN0的患者,术后放疗价值仍需进一步研究。 Objective To investigate the value of postoperative radiotherapy in patients with cT1-2N1M0 breast cancer after neoadjuvant chemotherapy and modified radical mastectomy which postoperative pathology showed that the number of axillary lymph node metastases was 0-3.Methods One hundred and twenty-eight patients diagnosed with cT1-2N1M0 breast cancer admitted to our hospital from January 1,2000 to December 31,2014 were retrospectively reviewed.All patients underwent neoadjuvant chemotherapy and modified radical mastectomy.The number of postoperative axillary lymph node metastases was 0-3.According to whether there was postoperative radiotherapy or not,the whole group of patients was divided into radiotherapy group(n=87)and non-radiotherapy group(n=41).In the two groups after operation,there were 43 and 11 patients with 1-3 axillary lymph node metastases(ypN1),while there were 44 and 30 patients without axillary lymph node metastases(ypN0)respectively.The 5-year locoregional recurrence-free survival(LRFS)rate,disease-free survival(DFS)rate and overall survival(OS)rate were calculated by Kaplan-Meier method,and the differences were compared by log-rank test.Univariate analysis was performed to analyze the effects of clinical features and treatment on prognosis.Results The 5-year LRFS rate,DFS rate and OS rate of 128 patients were 91.4%,82.8%and 93.0%respectively.The 5-year LRFS rates of the patients in the radiotherapy group and the non-radiotherapy group were 94.3%and 85.4%respectively,and the difference was not statistically significant(χ^2=3.055,P=0.080).As well as the 5-year DFS rates were 89.7%and 68.3%respectively,and the difference was statistically significant(χ^2=9.312,P=0.005).The 5-year OS rates were 94.3%and 90.2%respectively,and the difference was not statistically significant(χ^2=0.810,P=0.368).In the subgroup analysis,the 5-year LRFS rates of the patients who had achieved ypN1 in the radiotherapy group and the non-radiotherapy group were 93.0%and 72.7%,and the 5-year DFS rates were 88.4%and 63.6%,with statistically significant differences(χ^2=4.248,P=0.039;χ^2=4.525,P=0.033).The 5-year OS rates were 90.7%and 81.8%respectively,and the difference was not statistically significant(χ^2=0.713,P=0.399).The 5-year LRFS rates of the patients who had achieved ypN0 in the radiotherapy group and the non-radiotherapy group were 95.5%and 90.0%respectively,with no statistically significant difference(χ^2=0.872,P=0.350).The 5-year DFS rates were 90.9%and 70.0%respectively,with statistically significant difference(χ^2=5.439,P=0.019).The 5-year OS rates were 97.7%and 93.3%respectively,with no statistically significant difference(χ^2=0.876,P=0.349).The univariate analysis indicated that age(χ^2=11.709,P=0.001)and blood vessel invasion(χ^2=7.608,P=0.006)were significant influencing factors for 5-year LRFS rate.Postoperative radiotherapy(χ^2=9.312,P=0.002)was a prognostic factor for 5-year DFS rate.Age(χ^2=6.093,P=0.014)and hormone receptor status(χ^2=3.974,P=0.046)were prognostic factors for OS.Conclusion For the cT1-2N1M0 breast cancer patients with 1-3 positive axillary lymph nodes after neoadjuvant chemotherapy,postmastectomy radiotherapy has local control benefit,and it can improve DFS.However,the benefit of postoperative radiotherapy needs to be further investigated in patients with pathological negative axillary lymph nodes after neoadjuvant chemotherapy.
作者 孙丽云 卢月 张顺康 陈刚 Sun Liyun;Lu Yue;Zhang Shunkang;Chen Gang(Department of Radiation Oncology,Huangpu Branch of Shanghai Ninth People′s Hospital Affiliated to Shanghai Jiao Tong University School of Medicine,Shanghai 200011,China)
出处 《国际肿瘤学杂志》 CAS 2020年第1期10-17,共8页 Journal of International Oncology
基金 上海市黄浦区医疗卫生重点研究发展专科(HWZFK201804)。
关键词 乳腺肿瘤 预后 新辅助化疗 放射治疗 Breast neoplasms Prognosis Neoadjuvant chemotherapy Radiotherapy
  • 相关文献

参考文献1

二级参考文献16

  • 1No authors listed. Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer; anoverview of the randomised trials. Early Breast CancerTrialists' Collaborative Group[ J]. Lancet, 2000 , 355 (9217):1757-1770.
  • 2Senkus E, Kyriakides S, Penault-Llorca F, et al. Primarybreast cancer: ESMO Clinical Practice Guidelines fordiagnosis, treatment and follow-up [ J]. Ann Oncol,2013 ,24 Suppl 6 : vi7 -23.
  • 3Recht A, Edge SB, Solin U, et al. Postmastectomyradiotherapy : clinical practice guidelines of the AmericanSociety of Clinical Oncology"]. J Clin Oncol, 2001,19(5):1539-1569.
  • 4Goldhirsch A, Winer EP, Coates AS, et al. Personalizing thetreatment of women with early breast cancer: highlights of the StGallen International Expert Consensus on the Primary Therapyof Early Breast Cancer 2013[ J]. Ann Oncol, 2013, 24(9):2206-2223.
  • 5Clarke M, Collins R, Darfjy S, et al. Effects of radiotherapyand of differences in the extent of surgery for early breast canceron local recurrence and 15-year survival : an oyerview of therandomised trials[ J]. Lancet, 2005, 366(9503) :2087-2106.
  • 6Early Breast Cancer Trialists’ Collaborative Group, McGale P,Taylor C,et al. Effect of radiotherapy after mastectomy andaxillary surgery on 10-year recurrence and 20-year breast cancermortality : meta-analysis of individual patient data for 8135women in 22 randomised trials[J], Lancet, 2014, 383(9935):2127-2135.
  • 7Early Breast Cancer Trialists' Collaborative Group (EBCTCG)(Peto R,Davies C,et al. Comparisons between differentpolychemotherapy regimens for early breast cancer : meta-analyses of long-term outcome among 100,000 women in 123randomised trials[ J]. Lancet, 2012,379(9814) :432-444.
  • 8Early Breast Cancer Trialists’ Collaborative Group (EBCTCG),Darby S,McGale P, et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breastcancer death; meta-analysis of individual patient data for 10,801women in 17 randomised trialsf J]. Lancet, 2011, 378(9804):1707-1716.
  • 9von Minckwitz G, Untch M, Blohmer JU, et al. Definition andimpact of pathologic complete response on prognosis afterneoadjuvant chemotherapy in various intrinsic breast cancersubtypes[J]. J Clin Oncol, 2012,30(15) :1796-1804.
  • 10Taylor ME, Haffty BG, Rabinovitch R, et al. ACRappropriateness criteria on postmastectomy radiotherapy expertpanel on radiation oncology-breast[ J]. Int J Radiat Oncol BiolPhys, 2009 ’ 73(4) :997-1002.

共引文献6

同被引文献91

引证文献9

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部